The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias
Abstract
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, CH-associated clinical outcomes were dependent on GVHD prophylaxis, as a T cell-depleting post-transplant cyclophosphamide but not calcineurin inhibitor-based regimen, completely abrogated the effect of donor DNMT3A mutant CH on disease relapse and chronic GVHD 152 .”
From Clonal haematopoiesis and dysregulation of the immune system (2023) · cites this paper as [152]
In the citing paper
“Two independent studies of patients undergoing allogeneic HSC transplant for haematological malignancies reported that the presence of DNMT3A mutant CH in the donor cell product was associated with reduced risk of disease relapse and increased risk of chronic graft-versus-host disease (GVHD) 152,155 .”
From Clonal haematopoiesis and dysregulation of the immune system (2023) · cites this paper as [152]
In the citing paper
“Indeed, recipients of products with DNMT3A mutant donor CH had elevated serum levels of IL-12p70 152 ,”
From Clonal haematopoiesis and dysregulation of the immune system (2023) · cites this paper as [152]
In the citing paper
“Recent observations indicate that CH can affect outcomes in patients receiving cellular therapies for haematological malignancies.”
From Clonal haematopoiesis and dysregulation of the immune system (2023) · cites this paper as [152]
Citations
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Young, A. L., Challen, G. A., Birmann, B. M., & Druley, T. E. (2016) · Nature Communications · doi:10.1038/ncomms12484 · Cited by 692
Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis
McKerrell, T., Park, N., Moreno, T., Grove, C. S., Ponstingl, H., Stephens, J., Crawley, C., Craig, J., Scott, M. A., Hodkinson, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.005 · Cited by 534
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30626-x · Cited by 399
Gillis, N. K., Ball, M., Zhang, Q., Ma, Z., Zhao, Y., Yoder, S. J., Balasis, M. E., Mesa, T. E., Sallman, D. A., Lancet, J. E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30627-1 · Cited by 317
Research works printed but not linked: 11
- Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 20, 1472, 10.1038/nm.3733 · DOI · Paper page
- Kato, 2016, Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation, Leukemia, 30, 1742, 10.1038/leu.2016.23 · DOI
- Hertenstein, 2005, Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT), Haematologica, 90, 969
- Gondek, 2016, Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation, Leukemia, 30, 1916, 10.1038/leu.2016.63 · DOI
- Rojek, 2016, Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy, Biol Blood Marrow Transplant, 22, 2100, 10.1016/j.bbmt.2016.08.002 · DOI
- Kluk, 2016, Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies, J Mol Diagn, 18, 507, 10.1016/j.jmoldx.2016.02.003 · DOI · Paper page
- Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, 122, 3616, 10.1182/blood-2013-08-518886 · DOI · Paper page
- Walter, 2012, Clonal architecture of secondary acute myeloid leukemia, N Engl J Med, 366, 1090, 10.1056/NEJMoa1106968 · DOI
- Lindsley, 2015, Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood, 125, 1367, 10.1182/blood-2014-11-610543 · DOI · Paper page
- Kollman, 2016, The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy, Blood, 127, 260, 10.1182/blood-2015-08-663823 · DOI
- Gibson, Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma [published online ahead of print 9 January 2017]
Cited by
Age-related clonal hematopoiesis
Shlush, L. I. (2018) · Blood · doi:10.1182/blood-2017-07-746453 · Cited by 281
Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation
Frick, M., Chan, W., Arends, C. M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2184 · Cited by 223
Clonal haematopoiesis and dysregulation of the immune system
Belizaire, R., Wong, W. J., Robinette, M. L., & Ebert, B. L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00843-3 · Cited by 161
Clonal hematopoiesis: Mutation-specific adaptation to environmental change
Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129
Metadata
- Authors
- Gibson, C. J., Kennedy, J. A., Nikiforow, S., Kuo, F. C., Alyea, E. P., Ho, V., Ritz, J., Soiffer, R., Antin, J. H., & Lindsley, R. C.
- Affiliations
- Dana-Farber Cancer Institute, Boston, MA;
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; and
- Department of Pathology, Brigham and Women’s Hospital, Boston, MA
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-07-06
- Volume
- 130
- Issue
- 1
- Pages
- 91-94
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 82
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
